Quick Answer
Spero Therapeutics, Inc. reported Revenue (ASC 606) of $12.59 million for fiscal year 2025.
Spero Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $12.59M | +3292.5% |
| 2024 | $371.0K | -60.2% |
| 2023 | $933.0K | -62.7% |
| 2022 | $2.50M | -18.5% |
| 2021 | $3.07M | +1089.9% |
| 2020 | $258.0K | -94.6% |
| 2019 | $4.74M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | — |
| June 30, 2025 | $0.00 | -100.0% | -100.0% |
| March 31, 2025 | $12.0K | -91.4% | -81.5% |
| September 30, 2024 | $65.0K | -70.2% | -43.0% |
| June 30, 2024 | $114.0K | -57.6% | -18.6% |
| March 31, 2024 | $140.0K | -37.2% | -35.8% |
| September 30, 2023 | $218.0K | -79.9% | -19.0% |
| June 30, 2023 | $269.0K | -70.0% | +20.6% |
- Spero Therapeutics, Inc. showed an increase of +3292.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2025 period, Spero Therapeutics, Inc.’s revenue (asc 606) has grown by 165.4% (from $4.74 million to $12.59 million).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: